Tarsus to Participate in Upcoming Investor Conferences
30. Januar 2025 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
13. Januar 2025 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for...
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
13. November 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two...
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
13. November 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
06. November 2024 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
05. November 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
17. Oktober 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
25. September 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
28. August 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
08. August 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an...